JP6599848B2 - ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成 - Google Patents

ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成 Download PDF

Info

Publication number
JP6599848B2
JP6599848B2 JP2016513129A JP2016513129A JP6599848B2 JP 6599848 B2 JP6599848 B2 JP 6599848B2 JP 2016513129 A JP2016513129 A JP 2016513129A JP 2016513129 A JP2016513129 A JP 2016513129A JP 6599848 B2 JP6599848 B2 JP 6599848B2
Authority
JP
Japan
Prior art keywords
sortase
protein
erythrocyte
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016513129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519933A5 (enExample
JP2016519933A (ja
Inventor
ロデッシュ，ハーヴィー
プロー，ヒッド，エル．
リー，シャンイン
シ，ジアハイ
クンドラット，レンカ
ピシェシャ，ノヴァリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Publication of JP2016519933A publication Critical patent/JP2016519933A/ja
Publication of JP2016519933A5 publication Critical patent/JP2016519933A5/ja
Priority to JP2019182854A priority Critical patent/JP6960177B2/ja
Application granted granted Critical
Publication of JP6599848B2 publication Critical patent/JP6599848B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016513129A 2013-05-10 2014-05-09 ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成 Expired - Fee Related JP6599848B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019182854A JP6960177B2 (ja) 2013-05-10 2019-10-03 ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822071P 2013-05-10 2013-05-10
US61/822,071 2013-05-10
PCT/US2014/037554 WO2014183071A2 (en) 2013-05-10 2014-05-09 In vitro production of red blood cells with sortaggable proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019182854A Division JP6960177B2 (ja) 2013-05-10 2019-10-03 ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成

Publications (3)

Publication Number Publication Date
JP2016519933A JP2016519933A (ja) 2016-07-11
JP2016519933A5 JP2016519933A5 (enExample) 2017-06-22
JP6599848B2 true JP6599848B2 (ja) 2019-10-30

Family

ID=51867887

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016513129A Expired - Fee Related JP6599848B2 (ja) 2013-05-10 2014-05-09 ソルタギング可能なタンパク質を有する赤血球のｉｎｖｉｔｒｏ生成
JP2019182854A Expired - Fee Related JP6960177B2 (ja) 2013-05-10 2019-10-03 ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成
JP2021163272A Pending JP2022001063A (ja) 2013-05-10 2021-10-04 ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019182854A Expired - Fee Related JP6960177B2 (ja) 2013-05-10 2019-10-03 ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成
JP2021163272A Pending JP2022001063A (ja) 2013-05-10 2021-10-04 ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成

Country Status (7)

Country Link
US (3) US10471099B2 (enExample)
EP (4) EP3546484B1 (enExample)
JP (3) JP6599848B2 (enExample)
AU (2) AU2014262474B2 (enExample)
ES (1) ES2901383T3 (enExample)
HK (1) HK1222662A1 (enExample)
WO (1) WO2014183071A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012275390A1 (en) 2011-06-28 2014-01-16 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP4119662A1 (en) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP3546484B1 (en) 2013-05-10 2021-09-08 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
EP4372090A3 (en) 2013-11-07 2024-08-07 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
WO2015073746A2 (en) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
KR20220150986A (ko) 2014-04-01 2022-11-11 루비우스 테라퓨틱스, 아이엔씨. 면역조절을 위한 방법 및 조성물
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
MX376535B (es) 2014-12-17 2025-03-07 Hoffmann La Roche Reacción enzimática en un solo recipiente para conjugación de polipéptido doble en un solo paso usando sortasa.
CN107109463B (zh) 2014-12-17 2020-12-29 豪夫迈·罗氏有限公司 键形成酶的活性测定
WO2016183482A1 (en) * 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
EP3359573B1 (en) 2015-10-01 2023-01-04 The Whitehead Institute for Biomedical Research Labeling of antibodies
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
WO2017123644A1 (en) 2016-01-11 2017-07-20 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for immune indications
US10946102B2 (en) 2016-01-14 2021-03-16 North Carolina State University Glucose responsive insulin delivery compositions and methods
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
RU2019120400A (ru) 2016-12-02 2021-01-11 Рубиус Терапьютикс, Инк. Композиции и способы, связанные с клеточными системами для проникновения в солидные опухоли
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018151829A1 (en) * 2017-02-17 2018-08-23 Rubius Therapeutics, Inc. Functionalized erythroid cells
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3601562A1 (en) 2017-03-23 2020-02-05 President and Fellows of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3654991A1 (en) * 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for infectious disease
US20200172867A1 (en) 2017-07-19 2020-06-04 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cardiometabolic disease
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
US20200368285A1 (en) 2017-08-07 2020-11-26 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP4328314A3 (en) 2017-08-22 2024-03-20 Tessera Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
WO2019040649A1 (en) * 2017-08-23 2019-02-28 Whitehead Institute For Biomedical Research PRODUCTION OF REDUCED GLOBULATES AND USES THEREOF
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
JP2021500036A (ja) 2017-10-16 2021-01-07 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. アデノシン塩基編集因子の使用
US20190160102A1 (en) 2017-11-03 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
RU2021138205A (ru) * 2017-12-23 2022-01-20 Рубиус Терапьютикс, Инк. Искусственные антигенпрезентирующие клетки и способы их применения
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells
WO2019140116A2 (en) 2018-01-10 2019-07-18 Rubius Therapeutics, Inc. Amplifiable rnas for therapeutic cell systems
RU2020132924A (ru) 2018-03-08 2022-04-11 Рубиус Терапьютикс, Инк. Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
CN112996543A (zh) * 2018-09-21 2021-06-18 香港城市大学 表面修饰的细胞外囊泡
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN113366102A (zh) * 2018-12-03 2021-09-07 鲁比厄斯治疗法股份有限公司 包含hla-e和hla-g分子的人工抗原呈递细胞和使用方法
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3927354A1 (en) * 2019-02-20 2021-12-29 Rubius Therapeutics, Inc. Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
KR20210143230A (ko) 2019-03-19 2021-11-26 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20200338129A1 (en) 2019-04-26 2020-10-29 Rubius Therapeutics, Inc. Compositions including enucleated erythroid cells
SG11202111995TA (en) 2019-05-24 2021-12-30 Rubius Therapeutics Inc Methods of generating enucleated erythroid cells
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2023500327A (ja) 2019-11-04 2023-01-05 ルビウス セラピューティクス， インコーポレイテッド ミオイノシトールを使用して除核赤芽球細胞を生成する方法
EP4055148A1 (en) 2019-11-04 2022-09-14 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
US20230050813A1 (en) 2020-01-13 2023-02-16 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
CN115397395A (zh) * 2020-02-07 2022-11-25 加利福尼亚大学董事会 生物工程去核细胞的方法和用途
EP4103696A1 (en) 2020-02-10 2022-12-21 Rubius Therapeutics, Inc. Engineered erythroid cells including hla-g polypeptides and methods of use thereof
CN115335064B (zh) * 2020-03-20 2024-08-30 西湖生物医药科技(杭州)有限公司 修饰的红细胞及其用于递送药剂的用途
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
EP4149440A1 (en) * 2020-05-11 2023-03-22 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
WO2022089605A1 (en) * 2020-10-30 2022-05-05 Westlake Therapeutics (Hangzhou) Co. Limited Modified red blood cells and uses thereof for delivering agents
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
TW202241470A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 治療人類個體腫瘤之方法
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
WO2022164392A1 (en) * 2021-01-29 2022-08-04 National University Of Singapore Surface modified red blood cells and methods of generating the same
WO2022166913A1 (en) * 2021-02-04 2022-08-11 Westlake Therapeutics (Hangzhou) Co. Limited Modified red blood cells and uses thereof for treating hyperuricemia and gout
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
US20240180847A1 (en) 2021-03-31 2024-06-06 Carmine Therapeutics Pte. Ltd. Extracellular vesicles loaded with at least two different nucleic acids
TW202317179A (zh) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法
WO2023284742A1 (en) * 2021-07-13 2023-01-19 Westlake Therapeutics (Hangzhou) Co. Limited Cells modified by conjugated n-terminal glycine and uses thereof
CN120152732A (zh) * 2022-10-24 2025-06-13 西湖生物医药科技(上海)有限公司 诱导特异性免疫耐受的组合
AU2024252133A1 (en) * 2023-04-12 2025-10-16 Cytonus Therapeutics, Inc. Manufacturing of therapeutic cells
WO2025006882A1 (en) * 2023-06-30 2025-01-02 The Children's Hospital Of Philadelphia Click chemistry assisted cell surface engineering for restoring lentivirus entry

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
JP2000501614A (ja) 1995-12-15 2000-02-15 システミックス，インコーポレイテッド 高形質導入効率を有するレトロウイルスベクター上清を得るための方法
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1233780A4 (en) 1999-04-15 2004-09-22 Univ California IDENTIFICATION OF THE SORTASE GENE
US20020122768A1 (en) 2000-07-06 2002-09-05 Shuang Liu Stable radiopharmaceutical compositions and methods for preparation thereof
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US6960473B2 (en) * 2003-02-27 2005-11-01 Istituto Superiore Di Sanita In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
WO2005086654A2 (en) 2004-02-27 2005-09-22 The Trustees Of Princeton University Self-cleaving affinity tags and methods of use
EP1753859B1 (en) * 2004-06-04 2014-07-30 Université Pierre et Marie Curie (Paris 6) A method for producing red blood cells
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20110092961A1 (en) 2008-08-13 2011-04-21 Searete Llc Artificial cells
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
JP2010115136A (ja) 2008-11-12 2010-05-27 Teruyuki Nagamune Ｎ末端標識膜蛋白質の作製方法、及びｎ末端標識膜蛋白質を表層に有する細胞
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
RU2573994C2 (ru) 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
WO2011101468A1 (en) * 2010-02-22 2011-08-25 Université Pierre Et Marie Curie (Paris 6) Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
EP2593469A4 (en) 2010-04-20 2015-07-15 Whitehead Biomedical Inst MODIFIED POLYPEPTIDES AND PROTEINS AND ITS APPLICATION
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
AU2012275390A1 (en) 2011-06-28 2014-01-16 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102559600A (zh) 2011-12-29 2012-07-11 上海交通大学医学院 一种人工抗原递呈细胞及其在nk细胞扩增中的应用
EP2822957A1 (en) 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
EP2836507A4 (en) 2012-04-13 2016-08-24 Whitehead Biomedical Inst SORTAS-MODIFIED VHH DOMAINS AND USES THEREOF
US20140030697A1 (en) 2012-06-14 2014-01-30 Massachusetts Institute Of Technology Sortase-mediated modification of viral surface proteins
US9267127B2 (en) 2012-06-21 2016-02-23 President And Fellows Of Harvard College Evolution of bond-forming enzymes
US9511350B2 (en) 2013-05-10 2016-12-06 Clean Diesel Technologies, Inc. (Cdti) ZPGM Diesel Oxidation Catalysts and methods of making and using same
EP4119662A1 (en) 2013-05-10 2023-01-18 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
EP3546484B1 (en) 2013-05-10 2021-09-08 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
WO2014186508A1 (en) 2013-05-15 2014-11-20 University Of Rechester Human extensively self-renewing erythroblasts (esre)
WO2015051188A1 (en) 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
US9878045B2 (en) 2013-10-15 2018-01-30 Regents Of The University Of Minnesota Triorthogonal reagents for dual protein conjugation
WO2015073746A2 (en) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3359573B1 (en) 2015-10-01 2023-01-04 The Whitehead Institute for Biomedical Research Labeling of antibodies
WO2019040649A1 (en) 2017-08-23 2019-02-28 Whitehead Institute For Biomedical Research PRODUCTION OF REDUCED GLOBULATES AND USES THEREOF
SG11202111995TA (en) * 2019-05-24 2021-12-30 Rubius Therapeutics Inc Methods of generating enucleated erythroid cells

Also Published As

Publication number Publication date
JP2020018317A (ja) 2020-02-06
US10471099B2 (en) 2019-11-12
WO2014183071A2 (en) 2014-11-13
EP2994491A4 (en) 2016-12-07
AU2014262474B2 (en) 2019-10-31
US20160082046A1 (en) 2016-03-24
JP2016519933A (ja) 2016-07-11
US20180280440A1 (en) 2018-10-04
EP3693398A1 (en) 2020-08-12
US11992505B2 (en) 2024-05-28
JP6960177B2 (ja) 2021-11-05
ES2901383T3 (es) 2022-03-22
EP3546484B1 (en) 2021-09-08
AU2014262474A1 (en) 2015-12-17
HK1222662A1 (zh) 2017-07-07
JP2022001063A (ja) 2022-01-06
AU2019283766A1 (en) 2020-01-16
US20200069736A1 (en) 2020-03-05
EP3546485A1 (en) 2019-10-02
EP2994491A2 (en) 2016-03-16
AU2019283766B2 (en) 2022-01-27
EP3546484A1 (en) 2019-10-02
WO2014183071A3 (en) 2015-01-29
US11266695B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
JP6960177B2 (ja) ソルタギング可能なタンパク質を有する赤血球のｉｎ ｖｉｔｒｏ生成
CN106459918A (zh) 施加诱导多能干细胞产生过继细胞疗法产品
JP6019540B2 (ja) 抗原特異的又はリガンド特異的結合タンパク質の同定
US20200206269A1 (en) Production of enucleated red blood cells and uses thereof
KR20220162151A (ko) 항원 특이적 결합 폴리펩티드 유전자 디스플레이 벡터의 구축 방법 및 응용
CN113811363A (zh) 用于HvG病的治疗的CAR
KR20230136188A (ko) 유전적으로 변형된 간세포 집단
CN114921496A (zh) 一种具有nk细胞及adcc能力的人源化免疫系统动物模型的构建方法及其应用
CN115485293A (zh) 用于her2的嵌合抗原受体和其使用方法
US20240167006A1 (en) High production of recombinant protein by making cell hybrids and enriching for a preferred mitochondrial phenotype
HK40014900B (en) In vitro production of red blood cells with sortaggable proteins
HK40014900A (en) In vitro production of red blood cells with sortaggable proteins
HK40034057A (en) In vitro production of red blood cells with sortaggable proteins
HK40014485A (en) In vitro production of red blood cells with sortaggable proteins
CN110093359A (zh) 含cd3启动子序列和car序列的可分离的核酸及应用
WO2025128096A1 (en) High production of recombinant protein by making cell hybrids and enriching for a preferred mitochondrial phenotype
Winter et al. A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transduction in vivo
HK40113627A (zh) 一种检测抗体的试剂盒和方法
HK40113627B (zh) 一种检测抗体的试剂盒和方法
HK40085095A (en) Hypoimmunogenic cells
Moncivais Novel tools for the study of protein-protein interactions in pluripotent cells
WO2007034169A2 (en) Cell selection and reporter system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191003

R150 Certificate of patent or registration of utility model

Ref document number: 6599848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees